Nuevolution announced that Professor Paul Workman has joined as Scientific Advisor. Paul brings a vast knowledge and expertise within the oncology field to Nuevolution as well as profound understanding of bridging research discoveries with commercial value. Professor Workman is an exceptionally experienced research leader, having achieved a high level of success in academia, biotech companies and the pharmaceutical industry.

He is a Biochemist and Cancer Pharmacologist by training and he has worked at a number of academic institutions including Cambridge University, UK, Stanford University, California and the University of Glasgow, UK before moving to AstraZeneca, Alderley Park, UK as Head of the Cancer Bioscience Section in 1993. In 1997, Paul joined The Institute of Cancer Research (ICR), London to build the Cancer Research UK Cancer Therapeutics Unit (CTU) and also co-founded two successful biotech companies, Piramed Pharma and Chroma Therapeutics. As well as being the Director of the ICR's CTU and Harrap Professor of Pharmacology and Therapeutics, Paul was recently appointed Interim Chief Executive of ICR, having been Deputy CEO for the last 3 years.